Janssen Research & Development

New janssen phase 3 data in patients with moderately to severely active rheumatoid arthritis shows sirukumab significantly inhibited radiographic progression

by Rafiuzzaman Sifat - Jul 9, 2016

News Hour: Janssen Research & Development, LLC (Janssen) announced results from a pivotal Phase 3 study evaluating subcutaneous sirukumab (CNTO 136), a human anti-interleukin (IL)-6 monoclonal antibody in development for the treatment of adults with moderately...
Webcast presentation on phase 3 data for darzalex® (daratumumab) and the janssen immuno-oncology strategy and portfolio

by Rafiuzzaman Sifat - Jul 8, 2016

News Hour: Janssen Research & Development, LLC and Johnson & Johnson (NYSE: JNJ) provided a pre-recorded webcast focused on Phase 3 data recently presented for DARZALEX® (daratumumab) as well as the company’s immuno-oncology strategy and portfolio. The...

New janssen phase 3 data in patients with moderately to severely active rheumatoid arthritis shows sirukumab significantly inhibited radiographic progression